MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjcvp/pvaf074

Медицинская библиотека · European heart journal. Cardiovascular pharmacotherapy · 2025

Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug.

Fumagalli Stefano, Dovizio Melania, Mazzoni Stefania, Degli Esposti Luca, Santamaria Emanuele, Spanalatte Giulia, Fumagalli Carlo, Cagnoni Camilla, Tariello Arianna, Cerbai Elisabetta, Marchionni Niccolò

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

AIMS: Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients with chronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidence of atrial fibrillation (AF) compared with no-Ran prescription (No-Ran).

METHODS AND

RESULTS

The original population (N = 6.1 million) derived from the databases of the Italian National Health System; information concerned hospitalizations with the related diagnoses, drug therapy, follow-up clinical events and visits. Patients hospitalized between 2011 and 2020 for any cause and discharged with an ICD-9-CM CCS code were studied if AF had not been diagnosed before. The follow-up duration was 4.4 and 5.0 years for the Ran and the No-Ran cohorts, respectively. Study subjects were 171 015 (mean age: 72 years; men: 66%; Ran: N = 22 207; No-Ran: N = 148 808). After propensity score matching, Ran (N = 6384) and No-Ran (N = 25 536) cohorts were similar for age, sex, comorbidities and drug therapy. AF incidence during follow-up was 5.3% and 9.6% in the Ran and in the No-Ran cohorts, respectively, with a 41% drug-related lower risk of arrhythmia development in the Cox model (HR = 0.59, 95% CI: 0.53-0.67, P < 0.001). Also, Ran correlated with reduced incidence of brady-arrhythmias (P = 0.001) and ventricular tachy-arrhythmias (P = 0.049), and with lower mortality (P < 0.001).

CONCLUSION

Our study, performed in a subset of the Italian CCS population, showed that Ran therapy was safe and associated with a long-term reduced AF incidence.

Для цитирования: Fumagalli Stefano, Dovizio Melania, Mazzoni Stefania, Degli Esposti Luca, Santamaria Emanuele, Spanalatte Giulia, Fumagalli Carlo, Cagnoni Camilla, Tariello Arianna, Cerbai Elisabetta, Marchionni Niccolò. Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug.. European heart journal. Cardiovascular pharmacotherapy. 2025. DOI: 10.1093/ehjcvp/pvaf074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.